Background: There is a Th1/Th2 cytokine imbalance and expression of IL-17 in patients with brain tumours.We aimed to compare the levels of IL-17A and IL-6 in sera of glioma, meningioma and schwannoma patientsas well as in healthy individuals. Materials and
Methods: IL-17A and IL-6 levels were measured in sera of 38glioma, 24 meningioma and 18 schwannoma patients for comparison with 26 healthy controls by commercialELISA assays.
Results: We observed an increase in the IL-17A in 30% of glioma patients while only 4% and5.5% of meningioma and schwannoma patients and none of the healthy controls showed elevated IL-17A in theirsera (0.29±0.54, 0.03±0.15 and 0.16±0.68 vs. 0.00±0.00pg/ml; p=0.01, p=0.01 and p=0.001, respectively). Therewas also a significant decrease in the level of IL-6 in glioma patients compared to healthy controls (2.34±4.35 vs.4.67±4.32pg/ml; p=0.01). There was a direct correlation between the level of IL-17A and age in glioma patients(p=0.005). Glioma patients over 30 years of age had higher IL-17A and lower IL-6 in their sera compared tothe young patients. In addition, a non-significant grade-specific inverse trend between IL-17A and IL-6 wasobserved in glioma patients, where high-grade gliomas had higher IL-17A and lower IL-6.
Conclusions: Ourdata suggest a Th17 mediated inflammatory response in the pathogenesis of glioma. Moreover, tuning of IL-6and IL-17A inflammatory cytokines occurs during progression of glioma. IL-17A may be a potential biomarkerand/or immunotherapeutic target in glioma cases.